Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study

被引：41

作者：

Harada, Yasuhiko ^{[1
]}

Nagata, Yasunobu ^{[2
,3
]}

Kihara, Rika ^{[1
]}

Ishikawa, Yuichi ^{[1
]}

Asou, Norio ^{[4
]}

Ohtake, Shigeki ^{[5
]}

Miyawaki, Shuichi ^{[6
]}

Sakura, Toru ^{[7
]}

Ozawa, Yukiyasu ^{[8
]}

Usui, Noriko ^{[9
]}

Kanamori, Heiwa ^{[10
]}

Ito, Yoshikazu ^{[11
]}

Imai, Kiyotoshi ^{[12
]}

Suehiro, Youko ^{[13
]}

Kobayashi, Shinichi ^{[14
]}

Kitamura, Kunio ^{[15
]}

Sakaida, Emiko ^{[16
]}

Onizuka, Makoto ^{[17
]}

Takeshita, Akihiro ^{[18
]}

Ishida, Fumihiro ^{[19
]}

Suzushima, Hitoshi ^{[20
]}

Ishizawa, Kenichi ^{[21
]}

Naoe, Tomoki ^{[22
]}

Matsumura, Itaru ^{[23
]}

Miyazaki, Yasushi ^{[24
]}

Ogawa, Seishi ^{[2
]}

Kiyoi, Hitoshi ^{[1
]}

机构：

[1] Nagoya Univ, Dept Hematol & Oncol, Grad Sch Med, Nagoya, Aichi, Japan

[2] Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Kyoto, Japan

[3] Cleveland Clin, Dept Translat Hematol & Oncol Res, Taussig Canc Inst, Cleveland, OH 44106 USA

[4] Saitama Med Univ, Int Med Ctr, Dept Hematol, Hidaka, Japan

[5] Kanazawa Univ, Kanazawa, Ishikawa, Japan

[6] Tokyo Metropolitan Otsuka Hosp, Div Hematol, Tokyo, Japan

[7] Saiseikai Maebashi Hosp, Leukemia Res Ctr, Maebashi, Gunma, Japan

[8] Japanese Red Cross Nagoya First Hosp, Dept Hematol, Nagoya, Aichi, Japan

[9] Jikei Univ, Dept Internal Med, Div Clin Oncol & Hematol, Sch Med, Tokyo, Japan

[10] Kanagawa Canc Ctr, Dept Hematol, Yokohama, Kanagawa, Japan

[11] Tokyo Med Univ, Dept Hematol, Tokyo, Japan

[12] Sapporo Hokuyu Hosp, Dept Hematol, Sapporo, Hokkaido, Japan

[13] Natl Hosp Org Kyushu Canc Ctr, Dept Hematol, Fukuoka, Japan

[14] Natl Def Med Coll, Dept Internal Med, Div Hematol, Saitama, Japan

[15] Ichinomiya Municipal Hosp, Div Hematol, Ichinomiya, Japan

[16] Chiba Univ Hosp, Dept Hematol, Chiba, Japan

[17] Tokai Univ, Dept Hematol Oncol, Sch Med, Isehara, Kanagawa, Japan

[18] Hamamatsu Univ Sch Med, Dept Internal Med, Hamamatsu, Shizuoka, Japan

[19] Shinshu Univ, Dept Internal Med, Div Hematol, Sch Med, Matsumoto, Nagano, Japan

[20] Kumamoto Shinto Gen Hosp, Dept Hematol, Kumamoto, Japan

[21] Yamagata Univ, Dept Internal Med 3, Div Hematol & Cell Therapy, Fac Med, Yamagata, Japan

[22] Natl Hosp Org Nagoya Med Ctr, Nagoya, Aichi, Japan

[23] Kindai Univ, Fac Med, Dept Hematol & Rheumatol, Osaka, Japan

[24] Nagasaki Univ, Atom Bomb Dis Inst, Dept Hematol, Grad Sch Biomed Sci, Nagasaki, Japan

来源：

LEUKEMIA RESEARCH | 2018年 / 66卷

关键词：

Acute myeloid leukemia; Prognosis; Risk stratification; European LeukemiaNet; Genetics; SOMATIC MUTATIONS; RECOMMENDATIONS; MANAGEMENT; DIAGNOSIS; TET2; FLT3;

D O I：

10.1016/j.leukres.2018.01.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Many genetic alterations that are associated with the prognosis of acute myeloid leukemia (AML) have been identified, and several risk stratification systems based on the genetic status have been recommended. The European LeukemiaNet (ELN) first proposed the risk stratification system for AML in 2010 (ELN-2010), and recently published the revised system (ELN-2017). We validated the long-term prognosis and clinical characteristics of each ELN-2017 risk category in Japanese adult AML patients who were treated in the Japan Adult Leukemia Study Group (JALSG) AML-201 study. We demonstrated that the 3-risk category system of the ELN2017 successfully discriminated the overall survival and complete remission rates in our cohort in comparison with the 4-risk category of the ELN-2010. However, there were still genetic categories in which stratification of patients into favorable or intermediate risk categories was controversial; the low allelic ratio of FLT3-ITD was not necessarily associated with a better prognosis in patients with FLT3-ITD, and cytogenetic abnormalities may affect the prognosis in patients with favorable genetic lesions such as NPM1 and CEBPA mutations. As many molecular targeting agents, such as FLT3 inhibitors, have been developed, we must continue to modify the genetic risk stratification system to match the progression of therapeutic strategies.

引用

页码：20 / 27

页数：8

共 34 条

[1] PROPOSED REVISED CRITERIA FOR THE CLASSIFICATION OF ACUTE MYELOID-LEUKEMIA - A REPORT OF THE FRENCH-AMERICAN-BRITISH COOPERATIVE GROUP
BENNETT, JM
CATOVSKY, D
DANIEL, MT
FLANDRIN, G
GALTON, DAG
GRALNICK, HR
SULTAN, C
[J]. ANNALS OF INTERNAL MEDICINE, 1985, 103 (04) : 620 - 625
[2] Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations
Chou, Wen-Chien
Huang, Huai-Hsuan
Hou, Hsin-An
Chen, Chien-Yuan
Tang, Jih-Luh
Yao, Ming
Tsay, Woei
Ko, Bor-Sheng
Wu, Shang-Ju
Huang, Shang-Yi
Hsu, Szu-Chun
Chen, Yao-Chang
Huang, Yen-Ning
Chang, Yi-Chang
Lee, Fen-Yu
Liu, Min-Chih
Liu, Chia-Wen
Tseng, Mei-Hsuan
Huang, Chi-Fei
Tien, Hwei-Fang
[J]. BLOOD, 2010, 116 (20) : 4086 - 4094
[3] Integrative prognostic risk score in acute myeloid leukemia with normal karyotype
Damm, Frederik
Heuser, Michael
Morgan, Michael
Wagner, Katharina
Goerlich, Kerstin
Grosshennig, Anika
Hamwi, Iyas
Thol, Felicitas
Surdziel, Ewa
Fiedler, Walter
Luebbert, Michael
Kanz, Lothar
Reuter, Christoph
Heil, Gerhard
Delwel, Ruud
Lowenberg, Bob
Valk, Peter J. M.
Krauter, Juergen
Ganser, Arnold
[J]. BLOOD, 2011, 117 (17) : 4561 - 4568
[4] Mutation in TET2 in Myeloid Cancers
Delhommeau, Francois
Dupont, Sabrina
Della Valle, Veronique
James, Chloe
Trannoy, Severine
Masse, Aline
Kosmider, Olivier
Le Couedic, Jean-Pierre
Robert, Fabienne
Alberdi, Antonio
Lecluse, Yann
Plo, Isabelle
Dreyfus, Francois J.
Marzac, Christophe
Casadevall, Nicole
Lacombe, Catherine
Romana, Serge P.
Dessen, Philippe
Soulier, Jean
Viguie, Franck
Fontenay, Michaela
Vainchenker, William
Bernard, Olivier A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (22) : 2289 - 2301
[5] Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Doehner, Hartmut
Estey, Elihu
Grimwade, David
Amadori, Sergio
Appelbaum, Frederick R.
Buechner, Thomas
Dombret, Herve
Ebert, Benjamin L.
Fenaux, Pierre
Larson, Richard A.
Levine, Ross L.
Lo-Coco, Francesco
Naoe, Tomoki
Niederwieser, Dietger
Ossenkoppele, Gert J.
Sanz, Miguel
Sierra, Jorge
Tallman, Martin S.
Tien, Hwei-Fang
Wei, Andrew H.
Lowenberg, Bob
Bloomfield, Clara D.
[J]. BLOOD, 2017, 129 (04) : 424 - 447
[6] Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Doehner, Hartmut
Estey, Elihu H.
Amadori, Sergio
Appelbaum, Frederick R.
Buechner, Thomas
Burnett, Alan K.
Dombret, Herve
Fenaux, Pierre
Grimwade, David
Larson, Richard A.
Lo-Coco, Francesco
Naoe, Tomoki
Niederwieser, Dietger
Ossenkoppele, Gert J.
Sanz, Miguel A.
Sierra, Jorge
Tallman, Martin S.
Loewenberg, Bob
Bloomfield, Clara D.
[J]. BLOOD, 2010, 115 (03) : 453 - 474
[7] Acute myeloid leukaemia
Estey, Elihu
Doehner, Hartmut
[J]. LANCET, 2006, 368 (9550) : 1894 - 1907
[8] The role of different genetic subtypes of CEBPA mutated AML
Fasan, A.
Haferlach, C.
Alpermann, T.
Jeromin, S.
Grossmann, V.
Eder, C.
Weissmann, S.
Dicker, F.
Kohlmann, A.
Schindela, S.
Kern, W.
Haferlach, T.
Schnittger, S.
[J]. LEUKEMIA, 2014, 28 (04) : 794 - 803
[9] The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial
Grimwade, D
Walker, H
Oliver, F
Wheatley, K
Harrison, C
Harrison, G
Rees, J
Hann, I
Stevens, R
Burnett, A
Goldstone, A
[J]. BLOOD, 1998, 92 (07) : 2322 - 2333
[10] Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
Grimwade, David
Hills, Robert K.
Moorman, Anthony V.
Walker, Helen
Chatters, Stephen
Goldstone, Anthony H.
Wheatley, Keith
Harrison, Christine J.
Burnett, Alan K.
[J]. BLOOD, 2010, 116 (03) : 354 - 365

← 1 2 3 4 →